X0202 SCHEDULE 13D/A 0002126691-26-000001 0002126691 XXXXXXXX LIVE 2 Warrants to purchase Class A Common Stock, par value $0.0001 per share 04/15/2026 false 0001779128 092667104 Strata Critical Medical, Inc.

31 HUDSON YARDS 31 HUDSON YARDS NEW YORK NY 10001

Velibor Krstic 0041774839182 Via Baraggie 23 Ascona V8 6612 0002126691 N Krstic Velibor PF PF N V8 1485877.00 0.00 1485877.00 0.00 1485877.00 N 16.2 IN IN Warrants to purchase Class A Common Stock, par value $0.0001 per share Strata Critical Medical, Inc. 31 HUDSON YARDS 31 HUDSON YARDS NEW YORK NY 10001 Velibor Krstic Via Baraggie 23, 6612 Ascona, SWITZERLAND Private Investor NONE NONE SWITZERLAND The total amount of funds used by the Reporting Person to purchase the 1485877 Warrants reported herein was approximately 25291 dollars. All such funds were provided from the Reporting Person personal funds. Since the previous filing on April 8 2026 the Reporting Person increased his position to 16.21 percent of the Public Warrants (10.49 percent of total warrants). The Reporting Person believes that a Mandatory Exchange via Amendment is the only rational solution to stabilize the capital structure before the May 7 2026 expiration. Market Leadership and Financial Performance: The Issuer is the market leader in the transplant logistics industry and reported record results in 2025 with an Adjusted EBITDA of 14.1 million USD . Management has raised the 2026 Adjusted EBITDA target to between 29 and 33 million USD representing an annualized growth rate of over 30 percent . With over 110 million USD in total liquidity including 61.2 million USD in cash and undrawn JPMorgan facilities the Issuer is in a position of exceptional strength . Quorum and Strategic Conclusion: The Reporting Person notes that under the Warrant Agreement only 50 percent consent is required for an amendment. Given the positions held by Sponsor KSL (35.3 percent) and LMR Partners (13.3 percent) the Reporting Person hereby declares his immediate availability to provide written consent to exceed the 50 percent threshold and facilitate the exchange for the benefit of all shareholders. This availability coupled with the confirmation of acquisitions under exclusivity and the fact that the aircraft fleet remains unencumbered means there are no economic justifications to let the securities expire at zero . With the common stock SRTA maintaining a solid market valuation reflecting the record fundamentals of the Company the inaction of the Board would be interpreted as a premeditated destruction of value and a breach of fiduciary duty. Except as set forth above the Reporting Person has no current plans or proposals that relate to or would result in any of the actions listed in paragraphs (a) through (j) of Item 4 of Schedule 13D. As of April 15 2026 the Reporting Person beneficially owns 1485877 Warrants which represent approximately 16.21 percent of the 9166644 public warrants outstanding. This percentage is based on the number of Public Warrants reported by the Issuer in its Annual Report on Form 10-K for the year ended December 31 2025. Additionally for transparency the Reporting Person owns 26425 shares of Common Stock (SRTA) representing approximately 0.03 percent of the 86989143 shares of Common Stock outstanding as of February 24 2026. . The Reporting Person has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of all 1485877 Warrants and all 26425 shares of Common Stock reported in Item 5a. During the past 60 days the Reporting Person acquired an aggregate of 1485877 Warrants in open market transactions on the Nasdaq Stock Market for an aggregate purchase price of approximately 25291 dollars. Between April 9 2026 and April 15 2026 the Reporting Person purchased an additional 346484 Warrants at a weighted average price of approximately 0.017 dollars per Warrant. The most recent transaction which resulted in the Reporting Person changing his beneficial ownership by more than 1 percent of the class occurred on April 15 2026. No other person is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the Warrants or the shares of Common Stock reported herein. Not applicable. Except for the declaration of availability to provide written consent for the Warrant Agreement amendment as described in Item 4 there are no contracts arrangements understandings or relationships legal or otherwise among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer including but not limited to transfer or voting of any of the securities finder fees joint ventures loan or option arrangements puts or calls guarantees of profits division of profits or loss or the giving or withholding of proxies. NONE Krstic Velibor /s/ VELIBOR KRSTIC 04/16/2026